跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

33999

Supelco

利福昔明

VETRANAL®, analytical standard

登录查看公司和协议定价
所有图片(1)
别名:
4-脱氧-4′-甲基吡啶并[1′,2′-1,2]咪唑并[5,4-c]利福霉素 SV, 利福昔明
经验公式（希尔记法）:
C43H51N3O11
CAS号:
80621-81-4
分子量:
785.88
MDL编号:
MFCD00864973
UNSPSC代码:
41116107
PubChem化学物质编号:
329754738
NACRES:
NA.24

等级

analytical standard

质量水平

100

产品线

VETRANAL®

保质期

limited shelf life, expiry date on the label

技术

HPLC: suitable
gas chromatography (GC): suitable

应用

forensics and toxicology
pharmaceutical (small molecule)

格式

neat

SMILES字符串

CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(C)=C\C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)c5c(nc6cc(C)ccn56)c4c3C2=O

InChI

1S/C43H51N3O11/c1-19-14-16-46-27(18-19)44-32-29-30-37(49)25(7)39-31(29)40(51)43(8,57-39)56-17-15-26(54-9)22(4)28(42(53)55-10)23(5)36(48)24(6)35(47)20(2)12-11-13-21(3)41(52)45-33(34(32)46)38(30)50/h11-18,20,22-24,26,28,35-36,47-50H,1-10H3,(H,45,52)/b12-11+,17-15+,21-13-/t20-,22+,23-,24-,26+,28+,35-,36-,43+/m1/s1

InChI key

HIYLTQREEOINNF-HTEWPBCCSA-N

正在寻找类似产品? 访问 产品对比指南

相关类别

一般描述

Chemical structure: macrolide

应用

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

法律信息

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 3

个人防护装备

Eyeshields, Gloves, type N95 (US)

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Rifaximin may have a dramatic effect on hepatic encephalopathy.
Christopher Lamb et al.
Clinical medicine (London, England), 12(5), 489-490 (2012-10-30)
E Mattila et al.
Alimentary pharmacology & therapeutics, 37(1), 122-128 (2012-10-26)
Clostridium difficile can cause severe antibiotic-associated colitis. Conventional treatments with metronidazole and vancomycin improve symptoms, but after discontinuation of treatment, C. difficile infection (CDI) recurs in a number of patients. Rifaximin is a rifamycin-based non-systemic antibiotic that has effect against
Vishesh Kothary et al.
Antimicrobial agents and chemotherapy, 57(2), 811-817 (2012-11-28)
Escherichia coli is implicated in the pathogenesis of inflammatory bowel disease (IBD). Rifaximin, a nonabsorbable derivative of rifampin effective against E. coli, improves symptoms in mild-to-moderate IBD. However, rifaximin resistance can develop in a single step in vitro. We examined
Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin.
Leonard B Weinstock et al.
Journal of the American Academy of Dermatology, 68(5), 875-876 (2013-04-23)
Infection prevention considerations related to New Delhi metallo-β-lactamase Enterobacteriaceae: a case report.
Ramya Gopinath et al.
Infection control and hospital epidemiology, 34(1), 99-100 (2012-12-12)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门